BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.

When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results. While the life sciences giant continues to lead in financial scale, its bioprocessing unit missed expectations, signaling continued softness in broader biopharma demand. The news hit European supplier Sartorius AG, which traded lower […]

Digital PCR revenue surged over 20% as clinical diagnostics grew.

Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Q2 earnings and new guidance put Bio-Rad Laboratories in focus Bio-Rad Laboratories (BIO) drew investor attention after reporting second quarter 2026 results alongside fresh guidance. Sales held at US$651 million year over year, while net income and earnings per share from continuing operations increased. The company now expects third quarter 2026 revenue to be flat compared with the second quarter, which it describes as a typical pattern. Management guidance also points to a mid single digit...

Biocon’s updated valuation work now points to a fair value price target of ₹429.67, compared with the earlier figure of ₹416.53. Recent research on peers in life sciences and diagnostics highlights how analysts are weighing profitability plans and execution risk when assigning price targets, which helps explain why the shift for Biocon is measured rather than aggressive. As you read on, you will see how this latest move fits into the evolving Biocon narrative and what to watch next as new...

Moby summary of Bio-Rad Laboratories, Inc.'s Q2 2026 earnings call

Bio-Rad Laboratories Inc (BIO) navigates mixed Q2 with strong Digital PCR growth and Clinical Diagnostics recovery, offset by Life Science softness and China headwinds.

Bio-Rad Laboratories (NYSE:BIO) reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral basis, as continued softness in academic research markets weighed on its Life Science segment. Pre

Bio-Rad (BIO) delivered earnings and revenue surprises of +11.97% and -0.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Organic revenue still fell, yet a segment returning to growth and a raised outlook were enough to reprice the stock in a single session.